Germany's Merck sees long-term growth in cancer drug Erbitux

DARMSTADT, Germany (Reuters) - German healthcare company Merck KGaA expects to get a long-term boost from study results in June that showed its main cancer drug Erbitux has an edge over rival product Avastin.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news